peptid
antihiv
drug
fuzeon
analog
share
common
heptad
repeat
hr
sequenc
differ
function
domain
ie
pocketand
lipidbind
domain
pbd
lbd
respect
hypothes
novel
antihiv
peptid
may
design
use
artifici
sequenc
contain
multipl
copi
hr
motif
plu
zero
one
two
function
domain
surprisingli
found
peptid
contain
nonnatur
hr
sequenc
could
significantli
inhibit
infect
addit
pbd
andor
lbd
peptid
result
signific
improv
activ
result
suggest
artifici
hr
sequenc
may
serv
structur
domain
could
use
templat
design
novel
antivir
peptid
hiv
virus
class
fusion
protein
residu
nhr
region
pocket
play
critic
role
viral
fusion
maintain
stabil
format
believ
bring
viral
target
cell
membran
proxim
result
fusion
viru
target
cell
membran
synthet
peptid
deriv
chr
region
eg
highli
potent
inhibit
hiv
fusion
brand
name
fuzeon
gener
name
enfuvirtid
first
hiv
fusion
inhibitor
approv
us
fda
treatment
hivaid
share
common
hr
sequenc
structur
domain
contain
differ
function
domain
ie
lipidbind
domain
lbd
pocketbind
domain
pbd
respect
believ
chrpeptid
inhibit
hiv
fusion
interact
hr
sequenc
viral
nhr
region
block
core
format
base
line
evid
hypothes
novel
antihiv
peptid
could
design
use
artifici
sequenc
contain
multipl
copi
hr
motif
templat
design
seri
peptid
contain
artifici
hr
sequenc
plu
zero
one
two
function
domain
found
peptid
consist
nonnatur
sequenc
predict
form
coiledcoil
structur
exhibit
inhibitori
activ
cellcel
fusion
activ
replic
format
addit
lbd
andor
pbd
led
signific
increas
activ
therefor
studi
lay
theoreticalempir
groundwork
ration
design
novel
antivir
peptid
hiv
virus
class
fusion
protein
peptid
synthes
benzhydrylamin
mbha
resin
use
fmoc
strategi
cleav
resin
hydrogen
fluorid
ntermini
peptid
acetyl
ctermini
amid
peptid
purifi
revers
phase
high
perform
liquid
chromatographi
homogen
molecular
weight
peptid
confirm
malditofm
autoflex
iii
bruker
dalton
cellcel
fusion
determin
dye
transfer
assay
previous
describ
use
calcein
amlabel
iiib
chronic
infect
iiib
cell
effector
cell
cell
target
cell
inhibit
cell
fusion
hrpeptid
calcul
previous
describ
inhibitori
concentr
ic
calcul
use
calcusyn
softwar
inhibitori
activ
hrpeptid
iiib
replic
determin
previous
describ
briefli
cell
infect
iiib
presenc
absenc
hrpeptid
grade
concentr
fourth
day
postinfect
cultur
supernat
collect
assay
antigen
use
elisa
previous
describ
sixth
day
postinfect
indic
xtt
tetrazolium
dye
polysci
inc
warrington
pa
ad
cell
detect
cytopath
effect
cpe
inhibitori
activ
design
hrpeptid
format
determin
sandwich
elisa
previous
describ
briefli
peptid
preincub
hrpeptid
grade
concentr
min
follow
addit
incub
min
mixtur
ad
well
elisa
plate
precoat
purifi
rabbit
igg
murin
monoclon
antibodi
mab
biotinlabel
goatantimous
igg
streptavidinconjug
horseradish
peroxidas
sahrp
substrat
tmb
ad
sequenti
absorb
nm
measur
use
elisa
reader
ultra
tecan
durham
nc
secondari
structur
predict
design
hrpeptid
carri
np
web
server
http
npsapbilibcpfr
use
hnn
secondari
structur
predict
method
accord
crystal
structur
core
form
nhrpeptid
chrpeptid
predict
tertiari
structur
design
hrpeptid
interact
hrpeptid
model
use
pymol
program
http
pymolsourceforgenet
design
four
set
hrpeptid
amino
acid
residu
peptid
contain
artifici
sequenc
consist
five
copi
ident
hr
motif
tendenc
form
coiledcoil
structur
eg
eelakka
ii
peptid
contain
four
copi
hr
motif
plu
lbd
eelakka
waslwnwf
iii
peptid
contain
four
copi
hr
motif
plu
pbd
eg
eelakka
iv
peptid
contain
three
copi
hr
motif
plu
pbd
lbd
eelakka
waslwnwf
fig
design
peptid
base
follow
principl
first
peptid
contain
copi
artifici
design
hr
motif
total
differ
current
antihiv
peptid
share
natur
chr
sequenc
consist
three
differ
hr
motif
ie
ytslihslieesqnqqekneq
second
residu
posit
helic
wheel
hydrophob
amino
acid
eg
leu
l
ile
form
hydrophob
face
interact
residu
e
g
posit
helic
wheel
nhelic
third
residu
b
c
posit
helic
wheel
neg
charg
residu
eg
glu
e
f
g
posit
posit
charg
residu
ly
k
amino
acid
residu
form
hydrophil
face
interact
water
increas
peptid
solubl
fig
c
furthermor
acid
residu
b
c
posit
helic
wheel
interact
f
g
posit
respect
form
saltbridg
order
increas
helic
structur
stabil
peptid
fig
five
function
domain
pbd
lbd
ad
respect
nand
ctermini
hr
sequenc
mimick
chrpeptid
respect
design
hrpeptid
predict
display
mainli
conform
interact
nhrpeptid
shown
tabl
amino
acid
residu
conform
residu
mainli
local
ctermin
region
random
coil
conform
result
suggest
design
hrpeptid
tendenc
form
structur
shown
mix
equimolar
concentr
nhrpeptid
chrpeptid
result
format
highli
stabl
tertiari
structur
determin
xray
crystallographi
fig
model
helix
bundl
form
design
hrpeptid
pymol
program
found
design
hrpeptid
tendenc
interact
nhrpeptid
form
shown
fig
four
amino
acid
residu
locat
posit
magenta
may
interact
four
amino
acid
residu
g
posit
yellow
respect
howev
bind
complementar
residu
weaker
residu
lbd
introduc
appear
fig
critic
interact
remain
howev
addit
hydrophob
part
may
ad
hydrophob
interact
evid
current
avail
structur
contrari
introduct
pbd
made
critic
hydrophob
domain
avail
bind
pocket
region
probabl
similar
fashion
addit
pbd
lbd
hr
sequenc
eg
may
dramat
effect
overal
interact
peptid
ntrimer
inhibitori
activ
design
hrpeptid
mediat
cellcel
fusion
determin
dye
transfer
assay
surprisingli
three
peptid
contain
artifici
hr
sequenc
exhibit
inhibitori
activ
dosedepend
manner
somewhat
effect
howev
addit
lbd
pbd
cor
nterminu
respect
sequenc
result
signific
increas
fusion
inhibitori
activ
exampl
inhibitori
activ
cellcel
fusion
higher
addit
pbd
lbd
nand
ctermini
respect
sequenc
led
improv
membran
fusion
inhibitori
activ
eg
potent
tabl
inhibitori
activ
design
hrpeptid
iiib
replic
assess
measur
product
cpe
consist
inhibitori
activ
cellcel
fusion
three
hrpeptid
contain
artifici
hr
sequenc
exhibit
moder
inhibitori
activ
replic
addit
function
domain
lbd
andor
pbd
result
remark
enhanc
antivir
activ
instanc
inhibitori
activ
product
cpe
higher
respect
notabl
peptid
potent
inhibit
replic
tabl
result
suggest
antivir
activ
hrpeptid
depend
hr
sequenc
function
domain
believ
inhibit
hiv
fusion
target
cell
interact
viral
nhr
region
block
core
format
compar
potenti
inhibitori
activ
design
hrpeptid
format
sandwich
elisa
use
mab
shown
fig
peptid
contain
hr
sequenc
hr
sequenc
plu
lbd
exhibit
margin
inhibitori
activ
addit
pbd
pbd
lbd
hr
sequenc
led
signific
increas
inhibitori
activ
format
interestingli
format
inhibitori
activ
design
hrpeptid
correl
inhibitori
activ
cellcel
fusion
fig
result
suggest
design
hrpeptid
inhibit
hiv
fusion
interf
viral
fusogen
core
format
discoveri
peptid
creat
new
avenu
develop
viral
fusion
inhibitor
virus
class
membran
fusion
protein
result
fact
protein
contain
uniqu
nhr
chr
sequenc
use
similar
mechan
mediat
viral
fusion
entri
report
peptid
deriv
chr
region
class
membran
fusion
protein
also
effect
correspond
virus
simian
immunodefici
virus
siv
respiratori
syncyti
viru
rsv
ebola
viru
nipah
hendra
virus
sever
acut
respiratori
syndromeassoci
coronaviru
sarscov
thu
question
whether
novel
antivir
peptid
could
design
use
univers
hr
sequenc
consist
multipl
artifici
design
leucinezipp
motif
templat
test
hypothesi
first
design
synthes
three
peptid
contain
five
copi
uniqu
hr
motif
assess
potenti
activ
strikingli
peptid
exhibit
inhibitori
activ
cellcel
fusion
replic
although
potenc
moder
tabl
previou
studi
shown
antihiv
chrpeptid
contain
common
hr
sequenc
howev
peptid
contain
hr
sequenc
eg
weak
activ
addit
pbd
lpd
cterminu
hr
sequenc
eg
respect
result
signific
increas
hiv
fusion
inhibitori
activ
therefor
postul
addit
pbd
andor
lbd
peptid
contain
multipl
copi
hr
motif
eg
hra
might
also
improv
activ
follow
logic
design
synthes
three
set
peptid
ad
pbd
lbd
cterminu
hr
sequenc
test
activ
inde
peptid
contain
artifici
hr
sequenc
plu
one
function
domain
eg
display
improv
inhibitori
activ
cellcel
fusion
replic
interestingli
addit
pbd
lbd
nand
ctermini
hr
sequenc
eg
result
improv
activ
although
function
domain
critic
activ
hr
sequenc
structur
domain
also
import
determin
antivir
activ
design
hrpeptid
exampl
hrpeptid
contain
hra
motif
potent
contain
hrb
hrc
motif
inhibit
replic
tabl
studi
mechan
design
hrpeptid
inhibit
hiv
fusion
replic
compar
inhibitori
activ
format
found
inhibitori
activ
hrpeptid
format
correl
potenc
block
cellcel
fusion
fig
indic
peptid
inhibit
hiv
fusion
target
cell
interf
viru
core
format
critic
step
hiv
fusion
process
conclus
result
studi
suggest
hr
sequenc
antihiv
peptid
may
serv
structur
domain
support
shape
size
peptid
respons
interact
viral
nhr
domain
identifi
sever
artifici
hr
sequenc
consist
multicopi
hr
motif
could
use
templat
conjunct
addit
uniqu
function
domain
correspond
virus
design
novel
antivir
peptid
hiv
virus
class
fusion
protein
blue
red
sequenc
chelix
pocketand
lipidbind
domain
respect
w
pi
analyz
use
protparam
expasi
proteom
server
http
wwwexpasyorgtoolsprotparamhtml
b
associ
hrpeptid
peptid
form
form
hrpeptid
interact
hydrophob
amino
acid
residu
local
hydrophob
interfac
residu
posit
orang
posit
blue
nhelix
interact
posit
blue
posit
orang
nhelic
respect
form
intern
ntrimer
residu
posit
green
hrpeptid
interact
e
g
posit
red
nhelic
respect
form
c
hydrophob
hydrophil
interfac
design
hrpeptid
residu
posit
green
form
hydrophob
face
interact
hydrophob
face
nhelic
b
c
f
posit
yellow
form
hydrophil
face
interact
h
molecul
solut
predict
ionic
interact
basic
acid
amino
acid
residu
design
hrpeptid
acid
residu
b
c
posit
hrpeptid
interact
basic
residu
f
g
posit
peptid
respect
form
intramolecular
saltbridg
stabil
conform
molecular
model
analysi
interact
nhrpeptid
chrpeptid
hrpeptid
b
c
e
respect
hrpeptid
expect
interact
two
molecul
howev
clariti
one
peptid
blue
shown
hr
sequenc
design
hrpeptid
light
orang
green
respect
pbd
lbd
orang
red
respect
amino
acid
residu
posit
magenta
hrpeptid
interact
e
posit
yellow
one
molecul
residu
posit
white
hrpeptid
would
bind
g
posit
anoth
helix
shown
inhibit
hrpeptid
format
ic
valu
design
hrpeptid
inhibit
format
format
determin
sandwich
elisa
sampl
test
triplic
data
present
mean
sd
bar
b
correl
inhibitori
activ
design
hrpeptid
format
cellcel
fusion
